Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Hodgkin Disease 8Lymphoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Lymphoma, Large B-Cell, Diffuse 2Mycosis Fungoides 1Lymphomatoid Papulosis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Primary Cutaneous Anaplastic Large Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphatic Diseases 1Leukemia 1Immunoblastic Lymphadenopathy 1Hematologic Diseases 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cholecalciferol 1Brentuximab Vedotin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, Primary Cutaneous Anaplastic Large Cell × Brentuximab Vedotin × Clear all
NCT01352520 2026-01-20

SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
79 enrolled
DermatologicLymphoid

Hematologic Diseases, Lymphoma, Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis, Lymphoma, Primary Cutaneous Anaplastic Large Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡